The Food and Drug Administration has taken a significant step by approving a generic medication for an exceptionally rare brain disorder, while simultaneously distancing itself from previous suggestions that the drug could benefit a large number of individuals with autism.
Narrowed Focus on Strongest Evidence
On Tuesday, the agency announced its approval of leucovorin for children and adults diagnosed with a specific genetic condition that severely limits the delivery of folate, an essential form of vitamin B, to the brain. FDA officials estimate that this ultrarare condition impacts fewer than one in a million people across the United States.
This decision marks a substantial retreat from statements made during a White House news conference in September, where then-President Donald Trump and FDA commissioner Marty Makary highlighted that the drug was under review for potential benefits to patients with autism, some of whom exhibit a form of vitamin brain deficiency.
Contradicting Earlier Optimistic Claims
At that September event, Makary suggested the drug might help "20, 40, 50% of kids with autism." The conference followed pledges from Health Secretary Robert F. Kennedy Jr. to identify the cause of autism by that same month. However, senior FDA officials clarified to reporters on Monday that their review was deliberately narrowed to concentrate on the most robust evidence, which only supported the drug's application for patients with the rare mutation affecting brain folate levels.
FDA officials also highlighted that one study advocating the drug's use for autism was retracted earlier this year, further undermining the earlier assertions.
Understanding Leucovorin and Its Applications
Leucovorin is a metabolite of folate, which is crucial for healthy pregnancies and is commonly recommended for women before conception and during pregnancy. The current FDA label encompasses leucovorin's role in mitigating side effects of certain chemotherapy drugs and treating a rare blood disorder.
Patients affected by the condition targeted in Tuesday's approval often experience movement disorders, seizures, and other neurological issues that can mimic symptoms of autism. Despite this overlap, professional medical societies emphasize that it remains far from certain whether the drug aids individuals with autism.
Medical Community's Cautious Stance
The American Academy of Pediatrics does not endorse the routine use of leucovorin for autistic children, including those with cerebral folate deficiency. While acknowledging that some trials in this subset of patients "suggest potential benefit," the group notes that the research derives from small-scale studies, limiting its conclusiveness.
Prescription Trends and Supply Challenges
Unresolved questions about the drug's efficacy have not deterred U.S. doctors from prescribing it. A paper published in The Lancet last week revealed that leucovorin prescriptions for children aged 5 to 17 were 71% higher than usual in the three months immediately following Trump's late September news conference.
Additionally, families of children with autism have reported difficulties in getting prescriptions filled in recent weeks. In response, FDA officials stated that the agency is permitting imports of the drug by foreign manufacturers to alleviate supply shortages. Notably, the drug's original manufacturer, GSK, has no plans to reintroduce its version of the medication.
Origins of the Review and Underlying Theory
The initial decision to review the drug stemmed from discussions with an Arizona-based neurologist who prescribes it for autism patients and operates an online education business centered on this experimental treatment. The theory posits that some individuals with autism possess specific antibodies that obstruct folate from entering the brain.
However, organizations like the Autism Science Foundation point out that non-autistic relatives of people with the disorder often exhibit the same antibodies, indicating they may not be a causative factor in the condition.
Broader Context on Autism Research
While no single cause for autism has been identified, most researchers agree that scientific evidence points to a combination of genetic and environmental factors playing a significant role in its development.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation, though the AP maintains sole responsibility for all content.
